Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion.

Van Acker HH, Anguille S, De Reu H, Berneman ZN, Smits EL, Van Tendeloo VF.

Front Immunol. 2018 Apr 10;9:658. doi: 10.3389/fimmu.2018.00658. eCollection 2018.

2.

Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.

De Waele J, Marcq E, Van Audenaerde JR, Van Loenhout J, Deben C, Zwaenepoel K, Van de Kelft E, Van der Planken D, Menovsky T, Van den Bergh JM, Willemen Y, Pauwels P, Berneman ZN, Lardon F, Peeters M, Wouters A, Smits EL.

Oncoimmunology. 2017 Dec 12;7(3):e1407899. doi: 10.1080/2162402X.2017.1407899. eCollection 2018.

PMID:
29399410
3.

To the Brain and Back: Migratory Paths of Dendritic Cells in Multiple Sclerosis.

De Laere M, Berneman ZN, Cools N.

J Neuropathol Exp Neurol. 2018 Mar 1;77(3):178-192. doi: 10.1093/jnen/nlx114.

4.

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators.

N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.

PMID:
29231133
5.

Acute hantavirus infection presenting as haemolytic-uraemic syndrome (HUS): the importance of early clinical diagnosis.

Clement J, Lee APK, Verpooten GA, Laenen L, Vergote V, De Samblanx H, Berneman ZN, Van Ranst M, Maes P.

Eur J Clin Microbiol Infect Dis. 2018 Jan;37(1):135-140. doi: 10.1007/s10096-017-3113-6. Epub 2017 Oct 6.

PMID:
28986730
6.

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.

Anguille S, Van de Velde AL, Smits EL, Van Tendeloo VF, Juliusson G, Cools N, Nijs G, Stein B, Lion E, Van Driessche A, Vandenbosch I, Verlinden A, Gadisseur AP, Schroyens WA, Muylle L, Vermeulen K, Maes MB, Deiteren K, Malfait R, Gostick E, Lammens M, Couttenye MM, Jorens P, Goossens H, Price DA, Ladell K, Oka Y, Fujiki F, Oji Y, Sugiyama H, Berneman ZN.

Blood. 2017 Oct 12;130(15):1713-1721. doi: 10.1182/blood-2017-04-780155. Epub 2017 Aug 22.

7.

Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use.

Van den Bergh JMJ, Smits ELJM, Versteven M, De Reu H, Berneman ZN, Van Tendeloo VFI, Lion E.

J Immunol Res. 2017;2017:1975902. doi: 10.1155/2017/1975902. Epub 2017 Jul 13.

8.

Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion.

Van den Bergh JMJ, Smits ELJM, Berneman ZN, Hutten TJA, De Reu H, Van Tendeloo VFI, Dolstra H, Lion E, Hobo W.

Cancer Immunol Res. 2017 Aug;5(8):710-715. doi: 10.1158/2326-6066.CIR-16-0336. Epub 2017 Jun 21.

PMID:
28637876
9.

Adult acute precursor B-cell lymphoblastic leukemia presenting as hypercalcemia and osteolytic bone lesions.

Granacher NCP, Berneman ZN, Schroyens W, Van de Velde ALR, Verlinden A, Gadisseur APA.

Exp Hematol Oncol. 2017 Apr 11;6:9. doi: 10.1186/s40164-017-0071-8. eCollection 2017.

10.

Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells.

Van Acker HH, Beretta O, Anguille S, De Caluwé L, Papagna A, Van den Bergh JM, Willemen Y, Goossens H, Berneman ZN, Van Tendeloo VF, Smits EL, Foti M, Lion E.

Oncotarget. 2017 Feb 21;8(8):13652-13665. doi: 10.18632/oncotarget.14622.

11.

The Toughest Nut to Crack: Will We Ever Have a Preventive and Effective HIV-1 Vaccine?

Berneman ZN.

Mol Ther. 2016 Nov;24(11):1896-1897. doi: 10.1038/mt.2016.195. No abstract available.

12.

Immunomodulatory Effects of 1,25-Dihydroxyvitamin D3 on Dendritic Cells Promote Induction of T Cell Hyporesponsiveness to Myelin-Derived Antigens.

Lee WP, Willekens B, Cras P, Goossens H, Martínez-Cáceres E, Berneman ZN, Cools N.

J Immunol Res. 2016;2016:5392623. Epub 2016 Sep 14.

13.

Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells.

Van Acker HH, Anguille S, Willemen Y, Van den Bergh JM, Berneman ZN, Lion E, Smits EL, Van Tendeloo VF.

J Hematol Oncol. 2016 Sep 29;9(1):101.

14.

The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.

Willemen Y, Van den Bergh JM, Bonte SM, Anguille S, Heirman C, Stein BM, Goossens H, Kerre T, Thielemans K, Peeters M, Van Tendeloo VF, Smits EL, Berneman ZN.

Oncotarget. 2016 Nov 8;7(45):73960-73970. doi: 10.18632/oncotarget.12170.

15.

GMP-Grade mRNA Electroporation of Dendritic Cells for Clinical Use.

Derdelinckx J, Berneman ZN, Cools N.

Methods Mol Biol. 2016;1428:139-50. doi: 10.1007/978-1-4939-3625-0_9.

PMID:
27236797
16.

Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium.

Van de Velde AL, Beutels P, Smits EL, Van Tendeloo VF, Nijs G, Anguille S, Verlinden A, Gadisseur AP, Schroyens WA, Dom S, Cornille I, Goossens H, Berneman ZN.

Leuk Res. 2016 Jul;46:26-9. doi: 10.1016/j.leukres.2016.03.009. Epub 2016 Apr 16.

PMID:
27111858
17.

Altered molecular expression of TLR-signaling pathways affects the steady-state release of IL-12p70 and IFN-α in patients with relapsing-remitting multiple sclerosis.

Deckx N, Willekens B, Wens I, Eijnde BO, Goossens H, Van Damme P, Berneman ZN, Cools N.

Innate Immun. 2016 May;22(4):266-73. doi: 10.1177/1753425916642615. Epub 2016 Mar 31.

PMID:
27036414
18.

Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy.

Smits EL, Stein B, Nijs G, Lion E, Van Tendeloo VF, Willemen Y, Anguille S, Berneman ZN.

Methods Mol Biol. 2016;1393:27-35. doi: 10.1007/978-1-4939-3338-9_3.

PMID:
27033213
19.

In Vivo Interleukin-13-Primed Macrophages Contribute to Reduced Alloantigen-Specific T Cell Activation and Prolong Immunological Survival of Allogeneic Mesenchymal Stem Cell Implants.

Hoornaert CJ, Luyckx E, Reekmans K, Dhainaut M, Guglielmetti C, Le Blon D, Dooley D, Fransen E, Daans J, Verbeeck L, Quarta A, De Vocht N, Lemmens E, Goossens H, Van der Linden A, Roobrouck VD, Verfaillie C, Hendrix S, Moser M, Berneman ZN, Ponsaerts P.

Stem Cells. 2016 Jul;34(7):1971-84. doi: 10.1002/stem.2360. Epub 2016 Mar 28.

20.

12 Weeks of Combined Endurance and Resistance Training Reduces Innate Markers of Inflammation in a Randomized Controlled Clinical Trial in Patients with Multiple Sclerosis.

Deckx N, Wens I, Nuyts AH, Hens N, De Winter BY, Koppen G, Goossens H, Van Damme P, Berneman ZN, Eijnde BO, Cools N.

Mediators Inflamm. 2016;2016:6789276. doi: 10.1155/2016/6789276. Epub 2016 Jan 20.

21.

Rapid Exercise-Induced Mobilization of Dendritic Cells Is Potentially Mediated by a Flt3L- and MMP-9-Dependent Process in Multiple Sclerosis.

Deckx N, Wens I, Nuyts AH, Lee WP, Hens N, Koppen G, Goossens H, Van Damme P, Berneman ZN, Eijnde BO, Cools N.

Mediators Inflamm. 2015;2015:158956. doi: 10.1155/2015/158956. Epub 2015 Oct 29.

22.

Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy.

Anguille S, Smits EL, Bryant C, Van Acker HH, Goossens H, Lion E, Fromm PD, Hart DN, Van Tendeloo VF, Berneman ZN.

Pharmacol Rev. 2015 Oct;67(4):731-53. doi: 10.1124/pr.114.009456. Review.

23.

Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner.

Anguille S, Van Acker HH, Van den Bergh J, Willemen Y, Goossens H, Van Tendeloo VF, Smits EL, Berneman ZN, Lion E.

PLoS One. 2015 May 7;10(5):e0123340. doi: 10.1371/journal.pone.0123340. eCollection 2015.

24.

Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.

Willemen Y, Van den Bergh JM, Lion E, Anguille S, Roelandts VA, Van Acker HH, Heynderickx SD, Stein BM, Peeters M, Figdor CG, Van Tendeloo VF, de Vries IJ, Adema GJ, Berneman ZN, Smits EL.

Cancer Immunol Immunother. 2015 Jul;64(7):831-42. doi: 10.1007/s00262-015-1688-2. Epub 2015 Apr 12.

PMID:
25863943
25.

Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.

Van Craenenbroeck AH, Smits EL, Anguille S, Van de Velde A, Stein B, Braeckman T, Van Camp K, Nijs G, Ieven M, Goossens H, Berneman ZN, Van Tendeloo VF, Verpooten GA, Van Damme P, Cools N.

Transplantation. 2015 Jan;99(1):120-7. doi: 10.1097/TP.0000000000000272.

26.

Clinical use of dendritic cells for cancer therapy.

Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN.

Lancet Oncol. 2014 Jun;15(7):e257-67. doi: 10.1016/S1470-2045(13)70585-0. Review.

PMID:
24872109
27.

Except for C-C chemokine receptor 7 expression, monocyte-derived dendritic cells from patients with multiple sclerosis are functionally comparable to those of healthy controls.

Nuyts AH, Ponsaerts P, Van Tendeloo VF, Lee WP, Stein B, Nagels G, D'hooghe MB, Willekens B, Cras P, Wouters K, Goossens H, Berneman ZN, Cools N.

Cytotherapy. 2014 Jul;16(7):1024-30. doi: 10.1016/j.jcyt.2014.02.016. Epub 2014 May 20.

28.

Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia.

Verlinden A, Jansens H, Goossens H, van de Velde AL, Schroyens WA, Berneman ZN, Gadisseur AP.

Eur J Haematol. 2014 Oct;93(4):302-8. doi: 10.1111/ejh.12345. Epub 2014 May 16.

PMID:
24750350
29.

Neuroendocrine immunoregulation in multiple sclerosis.

Deckx N, Lee WP, Berneman ZN, Cools N.

Clin Dev Immunol. 2013;2013:705232. doi: 10.1155/2013/705232. Epub 2013 Dec 8. Review.

30.

Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.

Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN, Vergote I, Amant F, VAN Gool SW.

Anticancer Res. 2013 Dec;33(12):5495-500.

PMID:
24324087
31.

Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors.

Thewissen K, Nuyts AH, Deckx N, Van Wijmeersch B, Nagels G, D'hooghe M, Willekens B, Cras P, Eijnde BO, Goossens H, Van Tendeloo VF, Stinissen P, Berneman ZN, Hellings N, Cools N.

Mult Scler. 2014 Apr;20(5):548-57. doi: 10.1177/1352458513505352. Epub 2013 Sep 20.

PMID:
24057429
32.

Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy.

Anguille S, Lion E, Van den Bergh J, Van Acker HH, Willemen Y, Smits EL, Van Tendeloo VF, Berneman ZN.

Hum Vaccin Immunother. 2013 Sep;9(9):1956-61. doi: 10.4161/hv.25373. Epub 2013 Jun 18. Review.

33.

Dendritic cells: cellular mediators for immunological tolerance.

Chung CY, Ysebaert D, Berneman ZN, Cools N.

Clin Dev Immunol. 2013;2013:972865. doi: 10.1155/2013/972865. Epub 2013 May 15. Review.

34.

Interferon α may be back on track to treat acute myeloid leukemia.

Smits EL, Anguille S, Berneman ZN.

Oncoimmunology. 2013 Apr 1;2(4):e23619.

35.

Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies?

Nuyts AH, Lee WP, Bashir-Dar R, Berneman ZN, Cools N.

Mult Scler. 2013 Jul;19(8):995-1002. doi: 10.1177/1352458512473189. Epub 2013 Jan 31. Review.

PMID:
23369893
36.

Immunotherapy in leukaemia.

Van De Velde AL, Anguille S, Berneman ZN.

Acta Clin Belg. 2012 Nov-Dec;67(6):399-402. Review.

PMID:
23340144
37.

Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential.

Anguille S, Lion E, Tel J, de Vries IJ, Couderé K, Fromm PD, Van Tendeloo VF, Smits EL, Berneman ZN.

PLoS One. 2012;7(12):e51851. doi: 10.1371/journal.pone.0051851. Epub 2012 Dec 28.

38.

Identification of a Wilms' tumor 1-derived immunogenic CD4(+) T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes.

Anguille S, Fujiki F, Smits EL, Oji Y, Lion E, Oka Y, Berneman ZN, Sugiyama H.

Leukemia. 2013 Mar;27(3):748-50. doi: 10.1038/leu.2012.248. Epub 2012 Aug 29. No abstract available.

PMID:
22929521
39.

NK cells: key to success of DC-based cancer vaccines?

Lion E, Smits EL, Berneman ZN, Van Tendeloo VF.

Oncologist. 2012;17(10):1256-70. doi: 10.1634/theoncologist.2011-0122. Epub 2012 Aug 20. Review.

40.

Autologous T cells on the attack against AML.

Berneman ZN.

Blood. 2012 Aug 9;120(6):1151-2. doi: 10.1182/blood-2012-06-433177.

41.

Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.

Van Brussel I, Berneman ZN, Cools N.

Mediators Inflamm. 2012;2012:690643. doi: 10.1155/2012/690643. Epub 2012 Jul 18. Review.

42.

Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag-specific immune responses.

Van Gulck E, Cools N, Atkinson D, Bracke L, Vereecken K, Vekemans M, Van Tendeloo VF, Berneman ZN, Vanham G.

Clin Dev Immunol. 2012;2012:184979. doi: 10.1155/2012/184979. Epub 2012 Jul 12.

43.

Dendritic cell vaccination in acute myeloid leukemia.

Anguille S, Willemen Y, Lion E, Smits EL, Berneman ZN.

Cytotherapy. 2012 Jul;14(6):647-56. doi: 10.3109/14653249.2012.693744. Review.

PMID:
22686130
44.

Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.

Anguille S, Van Tendeloo VF, Berneman ZN.

Leukemia. 2012 Oct;26(10):2186-96. doi: 10.1038/leu.2012.145. Epub 2012 Jun 1. Review.

PMID:
22652755
45.

RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.

Snauwaert S, Vanhee S, Goetgeluk G, Verstichel G, Van Caeneghem Y, Velghe I, Philippé J, Berneman ZN, Plum J, Taghon T, Leclercq G, Thielemans K, Kerre T, Vandekerckhove B.

Haematologica. 2012 Oct;97(10):1539-47. doi: 10.3324/haematol.2012.065581. Epub 2012 Apr 24.

46.

A hypogranular variant of acute promyelocytic leukaemia showing a heterogenic immunophenotype with CD34, CD2, HLA-DR positivity: a case report and review of the literature.

Patteet L, Vermeulen K, Pieters K, Van Assche E, Vrelust I, Gaddiseur A, Berneman ZN, Van der Planken M.

Acta Clin Belg. 2012 Jan-Feb;67(1):34-8. Review.

PMID:
22480037
47.

Natural killer cell immune escape in acute myeloid leukemia.

Lion E, Willemen Y, Berneman ZN, Van Tendeloo VF, Smits EL.

Leukemia. 2012 Sep;26(9):2019-26. doi: 10.1038/leu.2012.87. Epub 2012 Mar 26. Review.

PMID:
22446501
48.

Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

Van Driessche A, Berneman ZN, Van Tendeloo VF.

Oncologist. 2012;17(2):250-9. doi: 10.1634/theoncologist.2011-0240. Epub 2012 Jan 30. Review.

49.

mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.

Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VF, Van De Velde A, Smits E, Anguille S, Cools N, Goossens H, Mertens L, De Haes W, Wong J, Florence E, Vanham G, Berneman ZN.

AIDS. 2012 Feb 20;26(4):F1-12. doi: 10.1097/QAD.0b013e32834f33e8.

PMID:
22156965
50.

Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC.

Lion E, Anguille S, Berneman ZN, Smits EL, Van Tendeloo VF.

PLoS One. 2011;6(6):e20952. doi: 10.1371/journal.pone.0020952. Epub 2011 Jun 17.

Supplemental Content

Loading ...
Support Center